Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04829552 · ClinicalTrials.gov registry record
Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units
A clinical trial of Covid19, sponsored by Corewell Health East.
- Completed
- Registry status
- 704
- Enrollment target
- 1
- Study location
NCT04829552 is a study of Covid19 that has completed, run by Corewell Health East. The registered enrollment target is 704 participants, below the 2,695-participant average among 94 other Covid19 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04829552, a study of Covid19, has completed, sponsored by Corewell Health East.
- COMPLETED
- Registry status
- 704 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.
Conditions Studied
Study Locations (1)
Michigan
- Beaumont Health System (BHS) - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 704 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2020-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04829552
The ClinicalTrials.gov registry entry for NCT04829552 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 704 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,695-participant average among 94 other Covid19 trials with a reported enrollment target (74% lower). The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 0 interventions.
NCT04829552 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04829552 about?
NCT04829552 is a clinical study titled "Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units". This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to ...
What is the current status of trial NCT04829552?
This trial is currently completed. The enrollment target is 704 participants. The study started on 2020-03-10. Estimated completion is 2020-04-15.
What conditions does trial NCT04829552 study?
This clinical trial studies the following conditions: Covid19.
Who is sponsoring clinical trial NCT04829552?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04829552 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
COVID-19 Vaccines International Pregnancy Exposure Registry
RECRUITING
-
COVID-19 Survivorship Registry
RECRUITING
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Conversations You Want About Corona Virus Disease (COVID-19)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.